The Global Weight Loss and Weight Management Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Weight Loss and Weight Management market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

I include (A) market snapshots, (B) the analysis sections you requested, and (C) a companies-with-values table (crisp, citable datapoints). Key sources are cited inline — the five most load-bearing sources are Grand View Research, Novo Nordisk annual report, Eli Lilly investor releases, MarketsandMarkets/other market houses, and recent news about generics / approvals.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/weight-loss-and-weight-management-market-12964

A — Market snapshot (representative estimates)
Grand View Research (weight-management market): global market estimated USD 142.58 billion (2022) with projection to USD ~298.66 billion by 2030 (CAGR ~9.94% for 2023–2030).

Expert Market Research / other houses: alternative estimates show the weight loss & weight management diet market ≈ USD 190.35 billion (2024) and projecting to ≈ USD 422.5B by 2034 (CAGR ~8.3%) — different vendors use different scopes (diet programs, drugs, supplements, services).

MarketsandMarkets / Markets reports: many forecasts for the weight-loss / obesity management market show mid-single to high-single digit CAGRs (6–10%+) depending on scope (drugs + devices + services + supplements).

Takeaway: estimates vary because firms define scope differently (prescription anti-obesity drugs and devices vs. whole ecosystem including supplements, programs and services). Consensus: a very large, multi-hundred-billion-dollar addressable market over the coming decade.

B — Requested analysis
Recent developments
GLP-1 / incretin revolution: rapid global uptake of GLP-1/Tirzepatide class meds (e.g., Novo Nordisk’s semaglutide formulations — Wegovy/Ozempic — and Eli Lilly’s tirzepatide products including Mounjaro/Zepbound) has dramatically reshaped market dynamics and demand. Novo Nordisk reported Wegovy sales of 58.2 bn DKK (~USD ~8B) in 2024, and both Novo Nordisk and Lilly saw major revenue lifts tied to obesity/diabetes medicines.

Supply & generics activity: regulators and generic players are entering the space (example: FDA approval news for a generic liraglutide by Teva), and some markets see increased activity by local suppliers/approvals (e.g., Aspen approval for Mounjaro pen in South Africa). These moves affect pricing dynamics and access.

Clinical efficacy & guideline attention for GLP-1s and next-generation agents (substantial weight-loss outcomes compared with older therapies).

Rising obesity prevalence and growing payer / employer interest in effective weight-management solutions.

Wider access channels (specialist clinics, primary care adoption, telehealth, DTC subscription services) and strong patient demand.

Restraints
Cost & reimbursement hurdles (high list prices and payer restrictions for chronic weight-management indications).

Supply constraints & safety/regulatory scrutiny (follow-on approvals, off-label use, compounding concerns) which can create short-term shortages or tighter controls.

Regional segmentation analysis
North America: early leader in spend and uptake (large commercial & Medicare influence on access).

Europe: strong clinical adoption in selected countries; reimbursement varies by country.

Asia-Pacific (including China/India): fastest volume growth potential as access expands and local manufacturers/compounding fill demand; regulatory timelines differ across markets.

Emerging trends
Next-gen molecules & combination therapies (GLP-1 + GIP dual agonists, e.g., tirzepatide class) and oral/less-frequent dosing formulations.

New commercial models: subscription clinics, employer-sponsored programs, telemedicine + pharmacy bundles.

Generic and biosimilar entrants for older agents (liraglutide etc.), expanding lower-cost access.

Top use cases
Chronic obesity management (primary care + specialist clinics) — long-term pharmacotherapy plus lifestyle support.

Metabolic disease co-management (type-2 diabetes, NASH risk reduction research).

Medical weight loss clinics & employer health programs.

Major challenges
Sustaining long-term adherence and addressing weight-regain when therapy stops.

Health-economics / payer coverage (cost vs demonstrated long-term outcomes).

Safety monitoring & managing off-label use / compounding risk.

Attractive opportunities
Adjunct services and coaching (digital therapeutics, apps, remote monitoring) to pair with drug therapy.

Market expansion in emerging regions as price and supply improve.

New molecules / improved delivery forms that expand patient eligibility and adherence.

Key factors of market expansion
Reimbursement decisions (payers covering chronic pharmacotherapy), manufacturing & supply scale-up, continued clinical evidence of long-term benefit, and competition driving price decreases (generics / biosimilars).

C — Companies (concrete datapoints with sources)
Company / product Concrete datapoint (value) Notes & source
Novo Nordisk — Wegovy / Ozempic (obesity & diabetes portfolio) Wegovy sales: 58.2 bn DKK (2024) (reported in Novo Nordisk’s annual summary — cited in company report / press coverage). Novo Nordisk Annual Report / reporting.
Eli Lilly — Mounjaro / Zepbound (tirzepatide) Q4 2024: revenue growth driven by Mounjaro; FY2024 notable uplift — Q2 2025: company reported revenue $15.56B (Q2 2025) with 38% growth driven by GLP uptake. Eli Lilly investor releases (Q4 2024, Q2 2025).
Teva FDA approval of a generic liraglutide (recent news item — first approved generic for a weight-loss drug), affecting pricing/competition. News on FDA generic liraglutide (Teva) approval.
Market (Grand View Research) Weight-management market: USD 142.58B (2022) → USD ~298.66B by 2030 (CAGR ~9.94%). Grand View Research market report.
Supplement & services submarkets (Grand View / Others) Weight-loss supplements market ~USD 33.14B (2024) — separate submarket estimates vary. Grand View Research (supplements).
Regional / supply news Pen approval & local launches (e.g. Aspen approval for Mounjaro pen in South Africa) — reflects geographic commercialization expansion and local competition. Reuters coverage — Aspen Mounjaro pen approval.
If you want, I can expand the table to include additional companies & precise product sales/quarter figures (Pfizer, Amgen, Novo’s Ozempic diabetes sales, compounding market estimates), or produce a CSV/PPT with the full source links.

Quick recommendations / next steps I can do right now
Pick one and I’ll generate it immediately (with source appendix included):

CSV of the company datapoints above + direct source links (great for Excel).

One-page PPTX: market scenarios (low/medium/high), company revenue bars (Novo Nordisk, Eli Lilly) and a source slide.

Deeper extract: pull quarterly sales breakdowns for Wegovy, Ozempic, Mounjaro, Zepbound and list country/regional splits (if available in investor slides).

Which output would you like me to build now? (I’ll create it immediately with source links.)